Skip to main content

Table 2 Associations between healthcare resource use and nintedanib adherence trajectory

From: Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Outcome

High adherence

Moderate adherence

High-then-poor adherence

Delayed-poor adherence

Early-poor adherence

Any all-cause inpatient hospital event

     

 Unadjusted mean

20.40%

22.80%

30.00%

29.40%

26.80%

 Unadjusted mean difference (95% CI)

ref

2.4% (− 4.0%, 8.9%)

9.6% (2.5%, 16.8%)

9.1% (2.8%, 15.3%)

6.4% (1.1%, 11.7%)

  P-value

 

0.46

0.008

0.005

0.02

 Adjusted mean difference (95% CI)

ref

2.4% (− 4.0%, 8.7%)

9.1% (2.2%, 16.0%)

8.0% (1.8%, 14.2%)

4.3% (− 0.8%, 9.4%)

  P-value

 

0.46

0.009

0.011

0.096

Count of all-cause inpatient hospital days

     

 Unadjusted mean

1.4

1.4

3.4

2

2.5

 Unadjusted mean difference (95% CI)

ref

0.0 (− 0.7, 0.7)

2.0 (0.7, 3.3)

0.7 (0.0, 1.3)

1.1 (0.4, 1.9)

  P-value

 

0.94

0.003

0.07

0.003

 Adjusted mean difference (95% CI)

ref

0.0 (− 0.7, 0.8)

1.8 (0.6, 2.9)

0.5 (− 0.1, 1.2)

0.8 (0.1, 1.5)

  P-value

 

0.9

0.003

0.11

0.02

Total all-cause medical spending

     

 Unadjusted mean

$12,648

$13,581

$17,550

$15,375

$18,110

 Unadjusted mean difference (95% CI)

ref

$933 (−$1,880, $3,746)

$4,902 ($768, $9,036)

$2,727 ($323, $5,131)

$5,462 ($2,521, $8,404)

  P-value

 

0.52

0.02

0.03

< 0.001

 Adjusted mean difference (95% CI)

ref

$523 (−$1,488, $2,534)

$4,876 ($1,470, $8,282)

$3,639 ($1,322, $5,955)

$3,907 ($1,658, $6,156)

  P-value

 

0.61

0.005

0.002

< 0.001

Any IPF-related inpatient hospital event

     

 Unadjusted mean

10.80%

11.40%

19.50%

14.10%

12.20%

 Unadjusted mean difference (95% CI)

ref

0.6% (− 4.3%, 5.5%)

8.7% (2.7%, 14.8%)

3.4% (− 1.4%, 8.2%)

1.4% (− 2.6%, 5.4%)

  P-value

 

0.8

0.005

0.17

0.49

 Adjusted mean difference (95% CI)

ref

0.8% (− 4.0%, 5.7%)

8.4% (2.5%, 14.2%)

3.0% (− 1.9%, 7.9%)

0.4% (− 3.4%, 4.2%)

  P-value

 

0.74

0.005

0.23

0.84

Count of IPF-related inpatient hospital days

     

 Unadjusted mean

0.7

0.6

1.9

0.7

0.9

 Unadjusted mean difference (95% CI)

ref

−0.2 (− 0.5, 0.2)

1.2 (0.3, 2.1)

0.0 (− 0.4, 0.4)

0.2 (− 0.2, 0.7)

  P-value

 

0.37

0.01

0.98

0.34

 Adjusted mean difference (95% CI)

ref

−0.2 (− 0.5, 0.1)

1.2 (0.4, 2.1)

0.1 (− 0.3, 0.5)

0.2 (− 0.2, 0.6)

  P-value

 

0.29

0.005

0.64

0.34

Total IPF-related medical spending

     

 Unadjusted mean

$3,240

$2,936

$6,012

$3,697

$3,861

 Unadjusted mean difference (95% CI)

ref

−$304 (−$1,075, $467)

$2,772 ($422, $5,122)

$457 (−$459, $1,372)

$621 (−$772, $2,014)

  P-value

 

0.44

0.02

0.33

0.38

 Adjusted mean difference (95% CI)

ref

−$299 (−$1,080, $482)

$2,205 ($455, $3,955)

$743 (−$244, $1,729)

$66 (−$815, $948)

  P-value

 

0.45

0.014

0.14

0.88

Sample size, n (%)

781 (43.4)

202 (11.2)

190 (10.6)

255 (14.2)

370 (20.6)

  1. Notes:
  2. 1. Dollar amounts inflated to 2019 USD using the Medical Care Consumer Price Index (August 10, 2022)
  3. 2. Results derived from models estimated with unadjusted linear regression or adjusted generalized linear models. Covariates in the adjusted model specifications included baseline measures of: age, sex, non-Hispanic White race and ethnicity, index year, Census region, SDI score, Gagne comorbidity count, gastroesophageal reflux disease, hypoxia, pulmonary hypertension, sleep apnea, CT scan, lung biopsy, oxygen receipt, index nintedanib prescriber was a pulmonologist, any all-cause ED event, any all-cause inpatient event, total prescription drug spending, and total medical spending
  4. 3. CI: confidence interval